New drug for Gao Xue's disease enters phase II clinical phase
-
Last Update: 2020-07-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
genz-112638, a new oral drug developed by Genzyme for the treatment of the rare genetic disease Gaucher, is now in Phase II clinical phaseGenzyme has published the data it obtained in Phase II clinical trialsHigh snow disease is an enzyme deficiency of hereditarydisease, symptoms include anemia, tiredness, fatigue and bleeding, such patients may also have liver and spleen enlargement, bone pain, bone necrosis and easy fracturesClinical observations have shown that the drug can quickly and significantly reach critical clinical endpoints -- including reducing the volume of the liver and spleen, increasing platelet readings, and increasing hemoglobin concentrationsIn the trial, the common side effects were minor and short-lived, and one subject showed more serious side effects, which are currently under examinationIt is reported that the drug will complete all clinical trials in mid-2008(Shi Lei)(reproduced from the Medical Economics Journal)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
